About Loyal
Loyal is a veterinary biotechnology company that develops pharmaceutical therapies for dogs aimed at extending their healthy lifespan and delaying age-associated diseases. It researches and formulates drug candidates designed to address the biological mechanisms of aging in different dog populations, including senior and large-breed dogs, with products progressing through clinical and regulatory pathways. Loyal engages in clinical studies and collaborates with veterinary professionals to advance its therapeutic programs and share scientific insights with the broader field. The company publishes research summaries to support transparency and enable other practitioners to build on its findings.
Open positions (5)
Company details
Funding
Total raised
$250M
Last stage
Growth
Investors
Founders
Celine Halioua
Founder and CEO of Loyal. Previously Chief of Staff at The Longevity Fund under Laura Deming. D.Phil. student at Oxford studying health economics of gene therapy. Background in neuroscience and nanobiotechnology from University of Texas at Austin.
LinkedInWhat happens next.
No applications, no recruiter spam. Just the intro.
Confirm the fit
A few questions to make sure this role is the right shape for you. Two minutes.
I pitch you to the company
I write the intro, send it to the founder, and handle the back-and-forth.
A meeting lands on your calendar
If they’re a yes, I book the chat. You show up — that’s the whole job-hunt.